New IRAK4 blocker AZD2962 enters human trials for Hard-to-Treat blood cancers
NCT ID NCT07064122
First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tests a new drug called AZD2962, which blocks a protein (IRAK4) involved in cancer growth. It is for people with certain blood cancers (MDS or CMML) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug helps shrink or control the cancer. About 72 participants will take the drug alone or with other medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGMiami, Florida, 33136, United States
-
Research Site
RECRUITINGTampa, Florida, 33612, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGHeidelberg, 3084, Australia
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
RECRUITINGShinagawa-ku, 141-0022, Japan
-
Research Site
RECRUITINGYoshida-gun, 910-1193, Japan
-
Research Site
WITHDRAWNSeoul, 05505, South Korea
-
Research Site
WITHDRAWNSeoul, 3722, South Korea
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGMadrid, 28027, Spain
-
Research Site
RECRUITINGMadrid, 28033, Spain
-
Research Site
RECRUITINGPamplona, 31008, Spain
-
Research Site
RECRUITINGSalamanca, 37007, Spain
-
Research Site
WITHDRAWNValencia, 46026, Spain
-
Research Site
NOT_YET_RECRUITINGKaohsiung City, 83301, Taiwan
-
Research Site
NOT_YET_RECRUITINGTainan, 70403, Taiwan
-
Research Site
RECRUITINGTaipei, 100, Taiwan
-
Research Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Research Site
RECRUITINGLondon, W1T 7HA, United Kingdom
-
Research Site
RECRUITINGManchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.